



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,563	05/26/2006	Susanne Matheus	MERCK-3169	5970
23599	7590	08/17/2009	EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			NOAKES, SUZANNE MARIE	
			ART UNIT	PAPER NUMBER
			1656	
			NOTIFICATION DATE	DELIVERY MODE
			08/17/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@mwzb.com

Office Action Summary	Application No.	Applicant(s)	
	10/580,563	MATHEUS ET AL.	
	Examiner	Art Unit	
	SUZANNE M. NOAKES	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 27 April 2009.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-3,8-13,17,18,21 and 22 is/are pending in the application.
 4a) Of the above claim(s) 17 and 18 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-3,8-13,21 and 22 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____. | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Status of the Claims

1. The amendments filed 27 April 2009 are acknowledged. Applicants have canceled claims 14, 15, 19 and 20. Thus, claims 1-3, 8-13, 17, 18, 21 and 22 are pending. Claims 17 and 18 remain withdrawn from consideration. Thus, claims 1-3, 8-13, 21 and 22 are subject to examination on the merits.

Information Disclosure Statement

2. The Examiner appreciates the information regarding the English language equivalents of the foreign documents cited. However, the point at issue is that Applicants have not submitted the foreign documents in the instant application. As such, said references will not be indicated as considered. It is noted in particular that for instance, the EP references cited and the "corresponding" US cases; there is no requirement that the EP document have the exact same disclosure as made for the US cases. If Applicants wish to have the "corresponding" US cases considered then it is suggested to submit a new IDS with these references; however, as the cited foreign references still have not been submitted as noted, said references will not be indicated as considered.

Withdrawal of Rejections/Objections

3. Any rejection/objection recited in the previous Office action and not explicitly restated below is hereby withdrawn.

4. All previous objections/rejections for claims 14, 15, 19 and 20 are effectively rendered moot in view of the cancellation of said claims.
5. The rejection of claim 13 under 35 USC 102(b) as anticipated by Li et al. is withdrawn in view of the incorporation of the limitation of now canceled claim 15 into claim 13, e.g. wherein the concentration is 50-150 mg/ml. Li et al. only teach 10 mg/ml.

The rejection of claim 13 under 35 USC 112 2nd paragraph is withdrawn in view of Applicants definition and clarification of the limitations in said claim. Namely, Applicants state that claim 13 is directed to crystalline forms for the claimed antibody and that the limitations of crystalline, soluble and suspended form are to mean that the crystals are in a solid form, e.g. tablets or depot formulation.

Maintained Rejections/Objections

Claim Rejections - 35 USC § 112 – 1st paragraph

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Enablement – Biological Deposits:

7. Claims 1-3, 8-13, 21 and 22 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

For Applicants convenience, the rejection is re-stated below:

It is apparent that anti-EGFR antibodies are required to practice the claimed invention. As required elements, ALL anti-EGFR antibodies encompassed by the claims must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If they are not so obtainable or available, the enablement requirements of 35 USC 112, first paragraph, may be satisfied by a deposit of the pertinent cell lines / hybridomas which produce these antibodies. See 37 CFR 1.801-1.809.

In addition to the conditions under the Budapest Treaty, applicant is required to satisfy that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent in U.S. patent applications.

Amendment of the specification to recite the date of deposit and the complete name and address of the depository is required. As an additional means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.

Applicant is reminded that the following and should amend the specification accordingly.

The current address of the ATCC is as follows:

American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209

If the original deposit is made after the effective filing date of an application for patent, the applicant should promptly submit a verified statement from a person in a position to corroborate the fact, and should state, that the biological material which is deposited is a biological material specifically identified in the application as filed, except if the person is an attorney or agent registered to practice before the Office, in which the case the statement need not be verified. See MPEP 1.804(b).

In the instant application, it is noted that the only anti-EGFR antibody used in the specification to make solid crystal anti-EGFR antibodies is ErbituxTM, also known as

MabC225 or cetuximab. Nonetheless, EMD 72000/matzumab/Mab h425 is claimed as well. While these antibodies may be publicly available for purchase, although Applicants do not say as much, the restrictions and assurances made by the owners of these products, which are directed to US patent 6217866 and US patent 5558864 (both cited on the instant IDS), have not been made on the instant record. As such, Applicants are required to indicate how the assurances and restrictions with regard to the public availability of these two anti-EGFR antibodies, as required and set forth above will be irrevocably removed should the instant application be allowable and issue as a United States patent.

Response by Applicants and Examiner's Rebuttal:

Applicants request that the instant rejection be held in abeyance until such time that the information which they are seeking from the ATCC is obtained regarding the public availability of the required deposited material. It is noted by Applicants that perhaps the hybridoma cell line number HB-9629 may have possibly changed since the original deposit and might explain why it does not appear on the publicly available list of hybridoma cell lines for the ATCC. As noted, Applicants are seeking clarification regarding this matter and all other required deposited material which are used to make the instant claimed invention (e.g. US 6,217,866 disclosed ATCC catalog Nos. HB 9763 and 9764 and the noted deposit of HB-9629 disclosed in US patent 5,558,864). With regard to the former deposits in the '866 deposit, Applicants are again encouraged to clarify which deposits relate to cetuximab and which to EMD72000, respectively.

Applicants are reminded that MPEP 2404.01 specifically states:

"The mere reference to a deposit or the biological material itself in any document publication does not necessarily mean that the deposited biological material is readily available. ***Even a deposit made under the Budapest Treaty and***

referenced in a United States or foreign patent document would not necessarily meet the test for known and readily available unless the deposit was made under conditions that are consistent with those specified in these rules, including the provision that requires, with one possible exception (37 CFR 1.808(b)), that all restrictions on the accessibility be irrevocably removed by the applicant upon the granting of the patent. Ex parte Hildebrand, 15 USPQ2d 1662 (Bd. Pat. App. & Int. 1990).

Applicants request that the instant rejection be held in abeyance until such time as the information sought is obtained is acknowledged. However, until such time, said rejection is also maintained.

Scope of Enablement:

Should the above deposit requirement and/or removal of restrictions along with the assurances be satisfied, the following 112 1st paragraph rejections apply.

8. Claims 1-3, 8-13, 21 and 22 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for solid crystals of whole murine humanized monoclonal antibodies of ErbituxTM/MabC225/Cetuximab (all synonyms of one another) produced by very specific crystallization methods and conditions of Example 2 and 3 only, does not reasonably provide enablement for crystals of comprising Mab h425/EMD 72000/matumumab antibodies and/or ErbituxTM/MabC225/Cetuximab wherein said antibodies have conserved substitutions, are glycosylated and/or deglycosylated and/or pegylated. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The claims are drawn to crystals of anti-EGFR antibodies of cetuximab or Mab h425 or variants thereof having conserved substitutions and/or glycosylated and/or deglycosylated and/or pegylateand which are made by precipitating an aqueous solution of said antibodies by means of a precipitating agent. However, the specification *only* sufficiently describes crystals that have been produced by the specific examples described in Examples 2 and 3 which discloses using ErbituxTM at a concentration of 20mg/ml in either 10 mM phosphate buffer at pH 8.0 or 10 mM citrate buffer at pH 5.5, adding either 10 mM phosphate buffer pH 8.0 to the phosphate protein solution or 10 mM citrate buffer pH 5.5 to the citrate protein solutions, respectively, and finally adding saturated ammonium sulfate in 10 mM phosphate buffer pH 8.0 to the phosphate protein-buffer solution or 50% v/v ethanol in 10 mM citrate buffer pH 5.5 to the citrate protein-buffer solution, respectively (it is noted that all additions are phosphate buffers to phosphate buffers and citrate buffers to citrate buffers/salts) and shaking this solution by hand for an undisclosed period of time at either room temperature or 4°C. It is presumed that the anti-EGFR antibody humanized monoclonal antibody ErbituxTM used in the crystallization procedures of Examples 2 and 3 is commercially purchased but this is not disclosed. Beyond this scope, however, the specification and claims are not sufficiently enabled for a skilled artisan not to have to endure a considerable amount of undue experimentation because: A) the specification does not disclose crystallization of variants of cetuximab (e.g. having conserved substitutions, are glycosylated and/or deglycosylated and/or pegylated, B) the specification does not disclose crystallization of Mab h425, variants or fragments thereof

whatsoever and C) there is considerably unpredictability in crystallizing any protein or antibody to begin. Furthermore, the specification states that this is the first time any anti-EGFR antibody has been crystallized, especially, Erbitux/MabC225/Cetuximab and thus there is no prior art teachings a skilled artisan can rely upon for help or guidance beyond the prior art of Li et al. (cited previously) which falls between the foreign priority date and the effective filing date of the instant PCT. Thus, a skilled artisan, in order to achieve the full scope of that which is being claimed, would be required to practice undue experimentation. In this case, the burden is seen as undue when the Wands analysis is considered.

The factors to be considered in determining whether undue experimentation is required are summarized *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988). The Court in Wands states: "Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.' " (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations." (*Wands*, 8 USPQ2d 1404). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state

of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. While all of these factors are considered, a sufficient amount for a *prima facie* case is discussed below.

In the instant case, the quantity of experimentation would be considerable because the smallest change in **any** parameter in crystallizing a protein/antibody can have enormous consequences. Thus, it is not enough to have the crystallization conditions of a related/similar protein/antibody or ‘native’ protein/antibody. Rather, what would be required is precise instruction about how to make each and every cetuximab and Mab h425 crystal including those having conserved substitutions and/or are glycosylated and/or deglycosylated and/or pegylated in order to avoid undue experimentation, and this includes precise instruction of how the protein/antibody was exactly produced and exactly purified, which include the noted assurances of public availability as noted above. However, beyond that which is described in Examples 2 and 3, there is no adequate direction or guidance in the specification of how a skilled artisan might achieve crystal growth of any other anti-EGFR antibody in any other conditions or with any other crystallization techniques (e.g. microbatch, macrobatch, sitting drop, capillary liquid-liquid diffusion etc.) other than full length ErbituxTM/MabC225/Cetuximab.

The nature of the invention and of the prior art suggests that crystallizing proteins and antibodies is an extremely tenuous science; what works for one protein or antibody does not necessarily work for another, and what works for one native protein or antibody does not necessarily work for a mutant or fragment or variant (even those with

Art Unit: 1656

conserved substitutions) even though they essentially contain the same protein/antibody that has already been crystallized. It is noted that Applicants attempted to crystallize Erbitux™ using a commercially available crystallization grid matrix screen, Crystal Wizard I, and were only able to successfully produce salt crystals (see Example 8). Thus, this also lends weight to the fact that crystallization of proteins and antibodies is not straight forward and is unpredictable at best. Specific overexpression protocols, precise protein purification protocols and exact crystallization conditions (e.g. temperature, buffer, salt, protein concentration etc.) are needed for each protein and/or antibody (see Weber, Overview of Crystallization Methods. Methods in Enzymology, 1997, Vol. 276, pp. 13-22).

The nature of the invention and of the prior art suggests that crystallizing proteins is an extremely tenuous science; what works for one protein does not necessarily for another, and what works for one native protein does not necessarily work for a mutant or a protein complex even though they contain the same protein that has already been crystallized. Specific crystallization conditions (e.g. temperature, buffer, salt, protein concentration etc.) are needed for each protein (or protein complex). McPherson (Eur. J. Biochem. 1990, 189:1-23) outlines 25 different parameters which do or could affect the crystallization of any protein (see Table 2, p. 13). It is stated (p. 13, 2nd column, *Factors influencing protein crystal growth*):

“Table 2 lists physical, chemical and biological variables that may influence to a greater or lesser extent the crystallization of proteins. The difficulty in properly arriving at a just assignment of importance for each factor is substantial for several reasons. Every protein is different in its properties and, surprisingly perhaps, this applies even to proteins that differ by no more than one or just a few amino acids. There are even cases where the identical protein

prepared by different procedures or at different times may show significant variations. In addition, each factor may differ considerably in importance for individual proteins.”

Thus, *at best*, the art of crystallization is unpredictable even to those skilled in the art who may either perform the experiments by hand or who are assisted by automated robotics because it often times requires thousands of individual experiments in order to find the one or two conditions that are successful for a single protein. Even then, there is no guarantee. It is even a well known fact in the art that luck often times play a fortuitous role in obtaining successful crystallization conditions despite the extremely high skill level of those in the art (see Drenth, “Principles of Protein X-Ray Crystallography”, 2nd Edition, 1999 Springer-Verlag New York Inc., Chapter 1, p. 19, 4th paragraph, lines 1-2). Furthermore, the prior art is of little assistance because while other antibodies have been crystallized, no anti-EGFR antibodies in any form (e.g. Fab fragments, single chain antibodies, etc.) have been successfully produced. Thus, when all things are considered and the Wands factors are treated on their merits, the claim is not enabled because a great deal of undue experimentation would be expected and necessary in order to practice the full scope of claimed invention.

Therefore, claims to all fragments and derivatives of cetuximab, Mab h425 crystals and fragments and derivatives thereof made by broad product by process, are not fully enabled beyond that described in Examples 2 and 3 for the whole murine humanized monoclonal antibody of Erbitux/MabC225/cetuximab.

Response by Applicants and Examiner's Rebuttal:

Applicants traverse the above rejection and submit that the specification, coupled with a skilled worker's knowledge, provides adequate guidance to make and use the instantly claimed compounds. Applicants describe in detail and enclose exhibits demonstrating the art-known methods/techniques for generating polypeptide variants based on (a) conserved amino acid substitutions; b) glycosylation of one or more amino acid residues; (c) deglycosylation of one or more amino acid residues; and (d) PEGylation of one or more amino acid residues.

The Examiner acknowledges these exhibits and has reviewed them carefully. However, the point which at the heart of the instant rejection does not lie in how readily accessible these polypeptide variants are to make (which again is acknowledged). The specific non-enabling point of the rejection is the unpredictability of crystallizing any protein or anti-body, even those derivatives or variants wherein the wild-type protein/antibody has previously been crystallized before. As taught by McPherson et al., there are over 25 different parameters affecting the success in crystallizing polypeptide/macromolecules such as proteins and antibodies and varying even one or two amino acids can change all of the parameters and one is forced to start again from scratch. Furthermore, while Applicants have disclosed at least how to make full length, unfragmented cetuximab, there is no disclosure or guidance whatsoever for Mab h425 and thus one skilled in the art does not even have a single example of where to begin or start with the later antibody because there is no expectation in this particular art that what works for one type of antibody/protein has any sort of relevance whatsoever for a

completely different protein/antibody. The same holds true for variants, even conserved variants, those which are deglycosylated or glycosylated.

As such, the scope of the claims exceeds that which is enabled by the specification and knowledge/unpredictability in the art.

Written Description:

9. Claims 1-3, 8-13, 21 and 22 are rejected under 35 U.S.C. § 112, first paragraph, written description, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The instant claims are drawn to a broad genus of crystals of anti-EGFR's, and those in pharmaceutical compositions and methods of making thereof. While the structure and function of some a single species of said genera of anti-EGFR antibody crystal is disclosed in the specification, the common characteristics of the species that define said genera are not described. Furthermore, the genus of anti-EGFR antibodies is very broad and diverse and the single species of Erbitux/MabC225/cetuximab described in the specification in crystalline form (Examples 2-3) is not representative of this entire genus of solid crystal anti-EGFR antibodies of C225 or h425 which have conservative substitutions, and/or are glycosylated and/or are deglycosylated and/or are pegylated.

The Court of Appeals for the Federal Circuit has recently held that a "written description of an invention involving a chemical genus, like a description of a chemical

species, ‘requires a precise definition, such as be structure, formula [or] chemical name,’ of the claimed subject matter sufficient to distinguish it from other materials.” University of California v. Eli Lilly and Co., 1997 U.S. App. LEXIS 18221, at *23, quoting Fiers v. Revel, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) (bracketed material in original). To fully describe a genus of genetic material, which is a chemical compound, applicants must (1) fully describe at least one species of the claimed genus sufficient to represent said genus whereby a skilled artisan, in view of the prior art, could predict the structure of other species encompassed by the claimed genus and (2) identify the common characteristics of the claimed molecules, e.g., structure, physical and/or chemical characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or a combination of these (Enzo Biochem 63 USPQ2d 1609 (CAFC 2002)).

The specification fully describes a single species of crystalline full length Erbitux/MabC225/cetuximab that are produced by a batch method which produces crystals from slightly different conditions that fall within the instant genera of crystals. Examples 2 and 3 describe the precise antibody/protein concentration and the buffer which said antibody is in and the exact crystallization conditions which results in crystals. Example 2 used 10 mM phosphate buffers at pH 8.0 and saturated ammonium sulfate in the same phosphate buffer to produce crystals whereas Example 3 used 10 mM citrate buffer at pH 5.5 and 50% ethanol in the same citrate buffer to produce crystals of Erbitux/MabC225/cetuximab. These two examples sufficiently and full describe a single species of anti-EGFR antibody crystals. However, these species do

not sufficiently describe the entire genus of cetuximab variant or fragment crystals, nor the genus of Mab h425 crystals (e.g. whole anti-body, variants and fragments thereof) antibody crystals.

In general, for a species of crystal to be adequately described, the following must be adequately disclosed in the specification and the claims: (1) the composition of the crystal (exact structural features of all molecules in the crystal must be described, including the protein/antibody (preferably a SEQ ID NO of all included residues) and any molecule bound to it) (2) the exact protein concentration and buffer the protein/antibody is in, (3) the exact temperature, buffers, salts, additives used for crystallization and 4) the technique used to obtain the crystal (e.g. vapor diffusion, microbatch, liquid-liquid diffusion, etc). The Erbitux/MabC225/cetuximab crystal species noted above have adequately met this burden. However, the process of obtaining the crystals which is encompassed by the breadth of the claims is not described sufficiently. A singular chemical composition can crystallize differently based on the crystallization conditions and techniques used (see, for example, Applicants failed attempts in Example 8). For example, if a skilled artisan wants to crystallize Erbitux/MabC225/cetuximab for structural studies, then the crystallization technique, buffer considerations, temperatures, etc. are going to very different than trying to crystallize a protein/antibody for therapeutic use because the overall objectives are so different and the quality of the crystals are important. While the instant claim broadly describes a process of precipitating the antibody solution with a precipitating agent, this is not enough.

However, based on the instant the specification, the chemical composition, the process of obtaining anti-EGFR antibodies in the first place, along with the process of obtaining crystals thereof, which are encompassed by the breadth of the claims is unpredictable to one of skill in the art. One of skill in the art would be unable to predict the structure of other members of the genera by virtue of the instant disclosure. Therefore, claims drawn to the instant genera of anti-EGFR antibody crystals are also not adequately described and the single species of Erbitux/MabC225/cetuximab crystals which fall within the structurally and functionally diverse genus is not deemed representative to claim the entire broad genus of anti-EGFR antibody crystals.

Response by Applicants and Examiner's Rebuttal:

Applicants assert that the amendments to claims overcome the written description rejection or record; however, to the extent said rejection is maintained, provide arguments in support of their assertions.

Applicants arguments described above for the 35 USC 112 1st paragraph scope of enablement are one and the same for the written description arguments, presumably (e.g. Applicants response to both the scope of enablement and written description were under a single heading/response). Applicants rebuttal as it pertains to the instant written description rejection is acknowledged.

However, as noted above, what is at issue is not how easily obtainable the variants of the polypeptides are or that there is extensive knowledge in the art how to obtain the claimed variants; the point at issue is these variant polypeptides in *crystalline*

form which are two very distinct issues. The genus of crystalline polypeptides/antibodies being claimed is large, variable and unpredictable. For inventions in emerging and/or unpredictable technologies, or for inventions characterized by factors not reasonably predictable which are known to one of ordinary skill in the art, more evidence is required to show possession. See, e.g., *Fiers v. Revel*, 984 F.2d at 1169, 25 USPQ2d at 1605; *Amgen*, 927 F.2d at 1206, 18 USPQ2d at 1021.

As such, the genus of *crystalline* antibodies exceeds that which is described in the specification, e.g. there is a single representative species of a crystalline antibody which is full length C225/cetuximab/Erbtitux™.

Conclusion

10. No claim is allowed.
11. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUZANNE M. NOAKES whose telephone number is (571)272-2924. The examiner can normally be reached on 7.00 AM-3.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Suzanne M. Noakes/
Primary Examiner, Art Unit 1656
03 August 2009